Accessibility settings

Published on in Vol 14 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/66246, first published .
Young woman lying on couch with stomach pain

Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial

Evaluating the Efficacy and Safety of 48-Week Low-Dose Dienogest Administration in Patients With Dysmenorrhea Caused by Endometriosis: Protocol for a Randomized, Open-Label, Parallel-Group Trial

Journals

  1. Kikuno K, Asada R, Ishihara T, Morishige K, Chikazawa K, Furui T, Isobe M. Efficacy and Safety of 48-Week Low-Dose Dienogest Treatment in Patients with Endometriosis-Associated Dysmenorrhea: A Randomized, Open-Label, Parallel-Group Trial. Advances in Therapy 2025;42(12):6248 View
  2. Nie J, Yan H, Jiang W. Analyzing the Risk Factors for Recurrence of Endometrioma and Dysmenorrhea in Patients with Endometriosis. International Journal of Women's Health 2026;Volume 18:1 View
  3. Foroughi Abari K, Derakhshandeh A, Tayefi F, Hosseini S, Salehi K, Hosseini S, Hossein Zehi Zamani E. Dual therapeutic role of dienogest and vitamin E in endometriosis management and cardiovascular risk modulation; a narrative review study. Journal of Preventive Epidemiology 2026;11(2):e39346 View